Abstract:Despite widespread drug exposure, for example during gestation or in prematurely born children, organ-specific developmental toxicity of most drugs is poorly understood. Developmental and functional abnormalities are a major cause of kidney diseases during childhood; however, the potential causal relationship to exposure with nephrotoxic drugs during nephrogenesis is widely unknown. To identify developmental nephrotoxic drugs in a large scale, we established and performed an automated high-content screen to score for phenotypic renal alterations in the Tg(wt1b:EGFP) zebrafish line. During early nephrogenesis, embryos were exposed to a compound library of approved drugs. After treatment, embryos were aligned within microtiter plates using 3D-printed orientation tools enabling the robust acquisition of consistent dorsal views of pronephric kidneys by automated microscopy. To qualitatively and quantitatively score and visualize phenotypes, we developed software tools for the semi-automated analysis, processing and visualization of this large image-based dataset. Using this scoring scheme, we were able to categorize compounds based on their potential developmental nephrotoxic effects. About 10% of tested drugs induced pronephric phenotypes including glomerular and tubular malformations, or overall changes in kidney morphology. Major chemical compound groups identified to cause glomerular and tubular alterations included dihydropyridine derivatives, HMG CoA reductase inhibitors, fibrates, imidazole, benzimidazole and triazole derivatives, corticosteroids, glucocorticoids, acetic acid derivatives and propionic acid derivatives. In conclusion, the presented study demonstrates the large-scale screening of kidney-specific toxicity of approved drugs in a live vertebrate embryo. The associated technology and tool-sets can be easily adapted for other organ systems providing a unique platform for in vivo large-scale assessment of organ-specific developmental toxicity or other biomedical applications. Ultimately, the presented data and associated visualization and browsing tools provide a resource for potentially nephrotoxic drugs and for further investigations.

In vivo zebrafish assays for analyzing drug toxicity

Application of zebrafish to safety evaluation in drug discovery

In vivo drug discovery in the zebrafish

Zebrafish models for assessing developmental and reproductive toxicity

Zebrafish Model in Drug Safety Assessment

An Integrated Microfluidic Array System for Evaluating Toxicity and Teratogenicity of Drugs on Embryonic Zebrafish Developmental Dynamics

Zebrafish Embryos and Larvae as Alternative Animal Models for Toxicity Testing

Zebrafish: a predictive model for assessing drug-induced toxicity

Zebrafish as a Successful Animal Model for Screening Toxicity of Medicinal Plants

Applications of Zebrafish Embryo Models to Predict Developmental Toxicity for Agrochemical Product Development

Zebrafish on a Chip: a Novel Platform for Real-Time Monitoring of Drug-Induced Developmental Toxicity.

Behavioral profiling of zebrafish embryos exposed to a panel of 60 water-soluble compounds

Comparison of the Zebrafish Embryo Toxicity Assay and the General and Behavioral Embryo Toxicity Assay as New Approach Methods for Chemical Screening

An Evaluation of Zebrafish, an Emerging Model Analyzing the Effects of Toxicants on Cognitive and Neuromuscular Function

In vivo High-Content Screening in Zebrafish for Developmental Nephrotoxicity of Approved Drugs

The posterity of Zebrafish in paradigm of in vivo molecular toxicological profiling

A high-throughput system for drug screening based on the movement analysis of zebrafish

Zebrafish as tools for drug discovery

Diving into drug-screening: Zebrafish Embryos as an in vivo Platform for Antimicrobial Drug Discovery and Assessment

Evaluation of in vitro toxicity information for zebrafish as a promising alternative for chemical hazard and risk assessment

Zebrafish (Danio rerio) as a model organism for screening nephrotoxic chemicals and related mechanisms